Other BiAb currently under clinical investigation include, e.g., BiTE molecules targeting CD20 in chronic lymphoblastic leukemia, CD33 in acute myeloid leukemia, and B cell maturation antigen (BCMA) in multiple myeloma [15•]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.